Confusion Persists Around the Interchangeability Designation for Biosimilars
Pharmacy Times,
With numerous adalimumab biosimilars launching in the United States in 2023, the impact of an FDA interchangeability…
With numerous adalimumab biosimilars launching in the United States in 2023, the impact of an FDA interchangeability…
With numerous adalimumab biosimilars launching in the US in 2023, the impact of an FDA interchangeability designation has been…
ABSTRACT Objectives: Biosimilars are highly similar to FDA-approved biologics, with no meaningful clinical difference between…
Sandoz evaluating next steps, including potential appeal to US Supreme Court Ruling continues to prevent launch of important…